Dr. Al-Ghamrawy, Chairman of the Egyptian Drug Authority, attended the signing ceremony of a cooperation agreement between Minapharm Pharmaceuticals and Bayer International in the New Capital under the auspices and in the presence of H.E. Prof. Dr. Khaled Abdel Ghaffar, Deputy Prime Minister and Minister of Health and Population, coinciding with the Global Conference on Population, Health and Development.
The ceremony was attended by distinguished officials, including Prof. Dr. Mohamed Awad Tag El-Din, Advisor to the President of the Republic for Health and Preventive Affairs, and Dr. Hisham Satit, Chairman of the Egyptian Authority for Unified Procurement, Medical Supply, and the Management of Medical Technology (UPA).
Minapharm Pharmaceuticals was represented by Dr. Wafik El Bardissi, Co-CEO and Executive Board Member. Representing Bayer Global were Dr. Hugo Hagen, Head of Global Health Unit; Ms. Caroline Weltzel, Global Health Lead; and Dr. Katrin Möllers, Head of Social Business Division.
Dr. Al-Ghamrawy affirmed that this agreement represents a strategic step towards localizing the pharmaceutical industry and transferring advanced technologies to the Egyptian market, emphasizing that the cooperation between Minapharm and Bayer embodies a successful model of partnership in supporting national manufacturing capabilities and enhancing Egypt’s position as a regional hub for pharmaceutical products manufacturing and export to the African continent.
He added that the collaboration aligns with Egypt’s national vision and the directives of the political leadership, which prioritize three strategic pillars: localizing pharmaceutical industries, advancing women’s health, and reinforcing Egypt’s role as a continental export hub.
He noted that the agreement supports the Presidential Initiative for Egyptian Women’s Health and the National Strategy for Population and Development (2023–2030) by expanding access to reproductive health and family planning services and improving the quality of healthcare services provided to women across governorates.
He further emphasized that this signing reflects the progress achieved by the Egyptian Drug Authority in attaining WHO Maturity Level 3, which has strengthened the development of the national pharmaceutical industry and facilitated procedures for registering and producing biological products. He stressed that the Authority has become a key pillar in implementing the state's strategy for pharmaceutical localization and achieving pharmaceutical products sufficiency for Egyptian citizens.
The signing ceremony was attended from the EDA by Dr. Tamer Elhossieny, Vice Chairman of the EDA, and Dr. Yasin Ragaey, Assistant Chairman of the EDA for Media Affairs and Investment Support and Supervisor of the Central Administration for Pharmaceutical Care.
The Egyptian Drug Authority reaffirms its continued support for national efforts aimed at localizing the pharmaceutical industry and enhancing the capacity of the local market to achieve self-sufficiency in strategic and biological products. The Authority also reiterates its commitment to implementing the directives of the political leadership by strengthening partnerships with major global companies and adopting cutting-edge pharmaceutical technologies, thereby consolidating Egypt’s position as a leading regional hub for pharmaceutical industries, research, and development at both regional and international levels.